Screener
CytomX Therapeutics CTMX Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337950
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Stockholders' equity: | ||
| Convertible preferred stock | — | — |
| Common stock | 2 | 2 |
| Additional paid-in capital | 1,053,125 | 810,844 |
| Accumulated other comprehensive income | (196) | 111 |
| Accumulated deficit | (750,863) | (711,949) |
| Total stockholders' equity | 302,068 | 99,008 |
| Total liabilities and stockholders' equity | $381,226 | $151,566 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is CytomX Therapeutics's total liabilities & equity?
- CytomX Therapeutics (CTMX) reported total liabilities & equity of $381.23M in Q2 2026.
- How has CytomX Therapeutics's total liabilities & equity changed year-over-year?
- CytomX Therapeutics's total liabilities & equity increased by 117.8% year-over-year, from $175.06M to $381.23M.
- What is the long-term trend for CytomX Therapeutics's total liabilities & equity?
- Over 5 years (2020 to 2025), CytomX Therapeutics's total liabilities & equity has grown at a -15.8% compound annual growth rate (CAGR), from $358.66M to $151.57M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about CytomX Therapeutics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude